The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor

Carcinogenesis

Volumn 31, Issue 2, 2010, Pages 167-174

  Xu, Xiao Lan ^a,b   Xing, Bao Cai ^b   Han, Hai Bo ^b   Zhao, Wei ^b   Hu, Mei Hao ^a   Xu, Zuo Liang ^b   Li, Ji You ^b   Xie, Yong ^c   Gu, Jun ^a   Wang, Yu ^b,d   Zhang, Zhi Qian ^b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^d Beijing ImmunoTech Applied Science Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA FETOPROTEIN; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CD56 ANTIGEN; CELL MARKER; CISPLATIN; DOXORUBICIN; EPIRUBICIN; HYDROXYCAMPTOTHECIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; PIRARUBICIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CASE REPORT; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE DELETION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SOUTHERN BLOTTING; WESTERN BLOTTING; ANIMAL; CELL ADHESION; COMPARATIVE STUDY; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MOUSE; MOUSE MUTANT; PATHOLOGY; TUMOR CELL CULTURE; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CISPLATIN; COMPARATIVE GENOMIC HYBRIDIZATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77649196191     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp232     Document Type: Article

References (45)

1. Parkin, D.M. et al. (2001) Estimating the world cancer burden: Globocan 2000. Int. J. Cancer, 94, 153-156.
2. Zhu, A.X. (2006) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist, 11, 790-800.
3. Bismuth, H. et al. (2000) Hepatobiliary surgery. J. Hepatol., 32, 208-224.
4. Reya, T. et al. (2001) Stem cells, cancer, and cancer stem cells. Nature, 414, 105-111.
5. Wicha, M.S. et al. (2006) Cancer stem cells: an old idea-a paradigm shift. Cancer Res., 66, 1883-1890; discussion 1895-1886.
6. Chiba, T. et al. (2006) Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology, 44, 240-251.
7. Suetsugu, A. et al. (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun., 351, 820-824.
8. Yin, S. et al. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer, 120, 1444-1450.
9. Ma, S. et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 132, 2542-2556.
10. Yang, Z.F. et al. (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell, 13, 153-156.
11. Clarke, M.F. et al. (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res., 66, 9339-9344.
12. Dean, M. et al. (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer, 5, 275-284.
13. Yu, F. et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109-1123.
14. Bao, S. et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-760.
15. Wulf, G.G. et al. (2001) A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood, 98, 1166-1173.
16. Haraguchi, N. et al. (2006) Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells, 24, 506-513.
17. Fillmore, C.M. et al. (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res., 10, R25.
18. Xu, X. et al. (2009) Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy. Cytotherapy, doi: 10.3109/14653240903390803.
19. Tamori, A. et al. (2005) Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin. Cancer Res., 11, 5821-5826.
20. Topaly, J. et al. (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia, 15, 342-347.
21. Yamamoto, T. et al. (1999) Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology, 29, 1446-1452.
22. Schmelzer, E. et al. (2006) The phenotypes of pluripotent human hepatic progenitors. Stem Cells, 24, 1852-1858.
23. Zheng, X. et al. (2007) Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res., 67, 3691-3697.
24. Sheridan, C. et al. (2006) CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res., 8, R59.
25. Moreb, J.S. (2008) Aldehyde dehydrogenase as a marker for stem cells. Curr. Stem Cell Res. Ther., 3, 237-246.
26. Ma, S. et al. (2008) Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res., 6, 1146-1153.
27. Ginestier, C. et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-567.
28. Duxbury, M.S. et al. (2004) A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res., 64, 3987-3993.
29. Zaniolo, K. et al. (2005) Regulation of the poly(ADP-ribose) polymerase-1 gene expression by the transcription factors Sp1 and Sp3 is under the influence of cell density in primary cultured cells. Biochem. J., 389, 423-433.
30. Miwa, M. et al. (2007) PolyADP-ribosylation and cancer. Cancer Sci., 98, 1528-1535.
31. Jagtap, P. et al. (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov., 4, 421-440.
32. Boulton, S. et al. (1999) Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis, 20, 199-203.
33. Lazaro, C.A. et al. (1998) Generation of hepatocytes from oval cell precursors in culture. Cancer Res., 58, 5514-5522.
34. Evarts, R.P. et al. (1987) A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis, 8, 1737-1740.
35. Alison, M.R. et al. (2005) Liver cancer: the role of stem cells. Cell Prolif., 38, 407-421.
36. Dan, Y.Y. et al. (2006) Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc. Natl Acad. Sci. USA, 103, 9912-9917.
37. Schmelzer, E. et al. (2007) Human hepatic stem cells from fetal and postnatal donors. J. Exp. Med., 204, 1973-1987.
38. Boyer, L.A. et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell, 122, 947-956.
39. Quintana, E. et al. (2008) Efficient tumour formation by single human melanoma cells. Nature, 4, 593-598.
40. Rich, J.N. et al. (2007) Chemotherapy and cancer stem cells. Cell Stem Cell, 1, 353-355.
41. Wang, E. et al. (2006) Clonal persistence and evolution during a decade of recurrent melanoma. J. Invest. Dermatol., 126, 1372-1377.
42. Durkacz, B.W. et al. (1980) (ADP-ribose)n participates in DNA excision repair. Nature, 283, 593-596.
43. Bryant, H.E. et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913-917.
44. Bowman, K.J. et al. (2001) Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer, 84, 106-112.
45. Shimizu, S. et al. (2004) Expression of poly(ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance. Oncol. Rep., 12, 821-825.